^
    Back
    Association details:
    Biomarker:EGFR N771_P772insVal
    Cancer:Lung Adenocarcinoma
    Drug:Ivesa (furmonertinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Medicine (Baltimore)
    Title:

    First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review

    Published date:
    12/29/2023
    Excerpt:
    The second case included a 40-year-old male who had an EGFR ex20ins mutation (p.N771_P772insVal). He had a good response to furmonertinib and exhibited stable disease according to response evaluation criteria in solid tumors with a progression-free survival of 10.90 months.
    DOI:
    10.1097/MD.0000000000036667